Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


8-Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis.

Odingo JO, Early JV, Smith J, Johnson J, Bailey MA, Files M, Guzman J, Ollinger J, Korkegian A, Kumar A, Ovechkina Y, Parish T.

Drug Dev Res. 2019 Aug;80(5):566-572. doi: 10.1002/ddr.21531. Epub 2019 Mar 20.


Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.

Robertson GT, Ektnitphong VA, Scherman MS, McNeil MB, Dennison D, Korkegian A, Smith AJ, Halladay J, Carter DS, Xia Y, Zhou Y, Choi W, Berry PW, Mao W, Hernandez V, Alley MRK, Parish T, Lenaerts AJ.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02071-18. doi: 10.1128/AAC.02071-18. Print 2019 Apr.


Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.

Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O'Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M.

Life Sci Alliance. 2018 Jun 1;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun.


Construction of an overexpression library for Mycobacterium tuberculosis.

Melief E, Kokoczka R, Files M, Bailey MA, Alling T, Li H, Ahn J, Misquith A, Korkegian A, Roberts D, Sacchettini J, Parish T.

Biol Methods Protoc. 2018;3(1):bpy009. doi: 10.1093/biomethods/bpy009. Epub 2018 Aug 20.


Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis.

Singh SB, Odingo J, Bailey MA, Sunde B, Korkegian A, O'Malley T, Ovechkina Y, Ioerger TR, Sacchettini JC, Young K, Olsen DB, Parish T.

BMC Res Notes. 2018 Jun 28;11(1):416. doi: 10.1186/s13104-018-3526-z.


Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.

Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Scullion P, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read KD, Green SR, Hipskind P, Parish T, Wyatt PG.

J Med Chem. 2018 Aug 9;61(15):6592-6608. doi: 10.1021/acs.jmedchem.8b00172. Epub 2018 Jul 26.


Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis.

Martinez-Grau MA, Valcarcel ICG, Early JV, Gessner RK, de Melo CS, de la Nava EMM, Korkegian A, Ovechkina Y, Flint L, Gravelle A, Cramer JW, Desai PV, Street LJ, Odingo J, Masquelin T, Chibale K, Parish T.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1758-1764. doi: 10.1016/j.bmcl.2018.04.028. Epub 2018 Apr 13.


The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis.

Korkegian A, O'Malley T, Xia Y, Zhou Y, Carter DS, Sunde B, Flint L, Thompson D, Ioerger TR, Sacchettini J, Alley MRK, Parish T.

Tuberculosis (Edinb). 2018 Jan;108:96-98. doi: 10.1016/ Epub 2017 Nov 7.


Corrigendum to "Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA" [Tuberculosis 107 (December 2017) 133-136].

McNeil MB, Dennison D, Shelton C, Flint L, Korkegian A, Parish T.

Tuberculosis (Edinb). 2018 May;110:123. doi: 10.1016/ Epub 2018 Feb 21. No abstract available.


Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.

McNeil MB, Dennison D, Shelton C, Flint L, Korkegian A, Parish T.

Tuberculosis (Edinb). 2017 Dec;107:133-136. doi: 10.1016/ Epub 2017 Sep 13. Erratum in: Tuberculosis (Edinb). 2018 Feb 8;:.


A Novel 6-Benzyl Ether Benzoxaborole Is Active against Mycobacterium tuberculosis In Vitro.

Patel N, O'Malley T, Zhang YK, Xia Y, Sunde B, Flint L, Korkegian A, Ioerger TR, Sacchettini J, Alley MRK, Parish T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01205-17. doi: 10.1128/AAC.01205-17. Print 2017 Sep.


The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.

Zuniga ES, Korkegian A, Mullen S, Hembre EJ, Ornstein PL, Cortez G, Biswas K, Kumar N, Cramer J, Masquelin T, Hipskind PA, Odingo J, Parish T.

Bioorg Med Chem. 2017 Aug 1;25(15):3922-3946. doi: 10.1016/j.bmc.2017.05.030. Epub 2017 May 19.


A Target-Based Whole Cell Screen Approach To Identify Potential Inhibitors of Mycobacterium tuberculosis Signal Peptidase.

Bonnett SA, Ollinger J, Chandrasekera S, Florio S, O'Malley T, Files M, Jee JA, Ahn J, Casey A, Ovechkina Y, Roberts D, Korkegian A, Parish T.

ACS Infect Dis. 2016 Dec 9;2(12):893-902. Epub 2016 Sep 19.


The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity.

Chandrasekera NS, Alling T, Bailey M, Korkegian A, Ahn J, Ovechkina Y, Odingo J, Parish T.

J Negat Results Biomed. 2015 Feb 13;14:4. doi: 10.1186/s12952-015-0024-x.


Mutations in the essential arabinosyltransferase EmbC lead to alterations in Mycobacterium tuberculosis lipoarabinomannan.

Korkegian A, Roberts DM, Blair R, Parish T.

J Biol Chem. 2014 Dec 19;289(51):35172-81. doi: 10.1074/jbc.M114.583112. Epub 2014 Oct 28.


Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.

Stolworthy TS, Korkegian AM, Willmon CL, Ardiani A, Cundiff J, Stoddard BL, Black ME.

J Mol Biol. 2008 Mar 28;377(3):854-69. doi: 10.1016/j.jmb.2008.01.002. Epub 2008 Jan 11.


Computational thermostabilization of an enzyme.

Korkegian A, Black ME, Baker D, Stoddard BL.

Science. 2005 May 6;308(5723):857-60.

Supplemental Content

Loading ...
Support Center